ATE472538T1 - 8-alk0xy-4-methyl-3, 4-dihydr0-chinaz0lin-2-yl- amine und ihre verwendung als 5-ht5a-rezeptor- liganden - Google Patents
8-alk0xy-4-methyl-3, 4-dihydr0-chinaz0lin-2-yl- amine und ihre verwendung als 5-ht5a-rezeptor- ligandenInfo
- Publication number
- ATE472538T1 ATE472538T1 AT06777337T AT06777337T ATE472538T1 AT E472538 T1 ATE472538 T1 AT E472538T1 AT 06777337 T AT06777337 T AT 06777337T AT 06777337 T AT06777337 T AT 06777337T AT E472538 T1 ATE472538 T1 AT E472538T1
- Authority
- AT
- Austria
- Prior art keywords
- disorders
- parkinson
- disease
- compounds
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05105699 | 2005-06-27 | ||
PCT/EP2006/063269 WO2007000393A1 (en) | 2005-06-27 | 2006-06-16 | 8-alk0xy-4-methyl-3 , 4-dihydr0-quinaz0lin-2-yl amines and their use as 5-ht5a receptor ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE472538T1 true ATE472538T1 (de) | 2010-07-15 |
Family
ID=37149153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06777337T ATE472538T1 (de) | 2005-06-27 | 2006-06-16 | 8-alk0xy-4-methyl-3, 4-dihydr0-chinaz0lin-2-yl- amine und ihre verwendung als 5-ht5a-rezeptor- liganden |
Country Status (14)
Country | Link |
---|---|
US (1) | US7790733B2 (de) |
EP (1) | EP1899307B1 (de) |
JP (1) | JP4769867B2 (de) |
KR (1) | KR100950629B1 (de) |
CN (1) | CN101208308B (de) |
AT (1) | ATE472538T1 (de) |
AU (1) | AU2006263925A1 (de) |
BR (1) | BRPI0613693A2 (de) |
CA (1) | CA2612478A1 (de) |
DE (1) | DE602006015193D1 (de) |
ES (1) | ES2345724T3 (de) |
IL (1) | IL188115A (de) |
MX (1) | MX2007015777A (de) |
WO (1) | WO2007000393A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2679938C (en) * | 2007-03-05 | 2016-08-02 | Benz Research And Development Corp. | Light filters comprising a naturally occurring chromophore and derivatives thereof |
CN101808999B (zh) * | 2007-09-27 | 2013-02-13 | 弗·哈夫曼-拉罗切有限公司 | 用作5ht5a受体拮抗剂的喹啉衍生物 |
FR2930891B1 (fr) * | 2008-05-06 | 2010-09-24 | Biocodex | Composes anti-amnesiants et compositions pharmaceutiques les comprenant |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06510538A (ja) * | 1991-09-06 | 1994-11-24 | 藤沢薬品工業株式会社 | キナゾリン誘導体およびそれらの製造方法 |
PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
GB0309781D0 (en) | 2003-04-29 | 2003-06-04 | Glaxo Group Ltd | Compounds |
EP1685115A1 (de) * | 2003-11-03 | 2006-08-02 | Warner-Lambert Company LLC | Neue norepinephrin-wiederaufnahmehemmer zur behandlung von erkrankungen des zentralen nervensystems |
-
2006
- 2006-06-16 MX MX2007015777A patent/MX2007015777A/es active IP Right Grant
- 2006-06-16 CA CA002612478A patent/CA2612478A1/en not_active Abandoned
- 2006-06-16 JP JP2008518783A patent/JP4769867B2/ja not_active Expired - Fee Related
- 2006-06-16 DE DE602006015193T patent/DE602006015193D1/de active Active
- 2006-06-16 WO PCT/EP2006/063269 patent/WO2007000393A1/en not_active Application Discontinuation
- 2006-06-16 AT AT06777337T patent/ATE472538T1/de active
- 2006-06-16 ES ES06777337T patent/ES2345724T3/es active Active
- 2006-06-16 EP EP06777337A patent/EP1899307B1/de not_active Not-in-force
- 2006-06-16 BR BRPI0613693-1A patent/BRPI0613693A2/pt not_active IP Right Cessation
- 2006-06-16 AU AU2006263925A patent/AU2006263925A1/en not_active Abandoned
- 2006-06-16 KR KR1020077030363A patent/KR100950629B1/ko not_active IP Right Cessation
- 2006-06-16 CN CN2006800229298A patent/CN101208308B/zh not_active Expired - Fee Related
- 2006-06-21 US US11/472,084 patent/US7790733B2/en not_active Expired - Fee Related
-
2007
- 2007-12-13 IL IL188115A patent/IL188115A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2612478A1 (en) | 2007-01-04 |
JP2008546823A (ja) | 2008-12-25 |
EP1899307A1 (de) | 2008-03-19 |
IL188115A (en) | 2011-09-27 |
US20060293350A1 (en) | 2006-12-28 |
US7790733B2 (en) | 2010-09-07 |
KR100950629B1 (ko) | 2010-04-01 |
WO2007000393A1 (en) | 2007-01-04 |
DE602006015193D1 (de) | 2010-08-12 |
IL188115A0 (en) | 2008-03-20 |
CN101208308A (zh) | 2008-06-25 |
EP1899307B1 (de) | 2010-06-30 |
AU2006263925A1 (en) | 2007-01-04 |
ES2345724T3 (es) | 2010-09-30 |
JP4769867B2 (ja) | 2011-09-07 |
CN101208308B (zh) | 2010-12-08 |
KR20080014082A (ko) | 2008-02-13 |
MX2007015777A (es) | 2008-02-22 |
BRPI0613693A2 (pt) | 2011-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009005509A (es) | 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a). | |
MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
ATE402935T1 (de) | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen | |
HRP20050780A2 (en) | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to thu use thereof | |
ATE454380T1 (de) | Organische verbindungen zur behandlung entzündlicher oder allergischer leiden | |
MY153979A (en) | Substituted piperidino-dihydrothienopyrimidine | |
DE602006010540D1 (de) | (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl)-amine mit aktivität am 5-ht-rezeptor | |
RS51631B (en) | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS β-SECRETASE INHIBITORS (BACE) | |
WO2005090296A3 (en) | N-substituted benzene sulfonamides | |
BRPI0406762A (pt) | Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça | |
ATE504580T1 (de) | Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit | |
ATE466858T1 (de) | 3-arylisoxazol-4-carbonylbenzofuranderivative | |
WO2007143523A3 (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
TW200602297A (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
EA200801302A1 (ru) | Композиции и способы лечения нарушений цнс | |
ATE466007T1 (de) | 5-substituierte indol-2-carbonsäureamidderivate | |
ATE472538T1 (de) | 8-alk0xy-4-methyl-3, 4-dihydr0-chinaz0lin-2-yl- amine und ihre verwendung als 5-ht5a-rezeptor- liganden | |
MX2010009403A (es) | Derivados de 2-aminoquinolina. | |
WO2007034326A3 (en) | Imidazole compounds for the treatment of neurological disorders | |
WO2010026110A3 (en) | 6-substituted benzoxazines as 5-ht-5a receptor antagonists | |
MX2010009820A (es) | 2-aminoquinolinas como antagonistas del receptor 5-hidroxitriptamina 5a. | |
MX2010008239A (es) | 2-aminoquinolinas. | |
ATE398614T1 (de) | Triazolverbindungen und ihre therapeutische verwendung | |
JP2006519251A5 (de) | ||
ATE461190T1 (de) | Substituierte pyradinon-derivate als alpha2- adrenorezeptor-antagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1899307 Country of ref document: EP |